Data Year:

For its 2025 fiscal year, CLOROX CO/DE, listed the following executives on its annual proxy statement to the SEC

Equity
Cash Compensation
Other
Fiscal Year Ended in 2025
Name And Title Total Compensation Pay Rank By Title In Biotechnology industry
Eric Reynolds
EVP and Chief Operating & Strategy Officer
Total Compensation $4,762,448 View details Pay Rank By Title In Biotechnology industry #27 View more
Kevin Jacobsen
Former EVP and Chief Financial Officer
Total Compensation $4,240,244 View details Pay Rank By Title In Biotechnology industry #79 View more
Linda Rendle
Chair and Chief Executive Officer (CEO)
Total Compensation $13,333,032 View details Pay Rank By Title In Biotechnology industry #62 View more
Chris Hyder
EVP and Group President-Health & Hygiene
Total Compensation $4,366,368 View details Pay Rank By Title In Biotechnology industry #45 View more
Nina Barton
EVP and Group President-Care & Connection
Total Compensation $10,070,862 View details Pay Rank By Title In Biotechnology industry #7 View more
Luc Bellet
EVP and Chief Financial Officer (CFO)
Total Compensation $2,622,296 View details Pay Rank By Title In Biotechnology industry #186 View more

The charts on this page feature a breakdown of the total annual pay for the top executives at CLOROX CO/DE as reported in their proxy statements.

Total Cash Compensation information is comprised of yearly Base Pay and Bonuses. CLOROX CO/DE income statements for executive base pay and bonus are filed yearly with the SEC in the edgar filing system. CLOROX CO/DE annual reports of executive compensation and pay are most commonly found in the Def 14a documents.

Total Equity aggregates grant date fair value of stock and option awards and long term incentives granted during the fiscal year.

Other Compensation covers all compensation-like awards that don't fit in any of these other standard categories. Numbers reported do not include change in pension value and non-qualified deferred compensation earnings.

Name And Title Total Cash Equity Other Total Compensation
Eric Reynolds
EVP and Chief Operating & Strategy Officer
Total Cash $1,491,523 Equity $2,999,828 Other $271,097 $4,762,448
Kevin Jacobsen
Former EVP and Chief Financial Officer
Total Cash $1,163,575 Equity $2,799,730 Other $276,939 $4,240,244
Linda Rendle
Chair and Chief Executive Officer (CEO)
Total Cash $3,003,692 Equity $9,754,753 Other $574,587 $13,333,032
Chris Hyder
EVP and Group President-Health & Hygiene
Total Cash $1,155,231 Equity $2,999,203 Other $211,934 $4,366,368
Nina Barton
EVP and Group President-Care & Connection
Total Cash $1,961,885 Equity $7,998,301 Other $110,676 $10,070,862
Luc Bellet
EVP and Chief Financial Officer (CFO)
Total Cash $877,077 Equity $1,599,673 Other $145,546 $2,622,296
For its 2025 fiscal year, CLOROX CO/DE, listed the following CEO pay ratio data on its annual proxy statement to the SEC.
CEO Name CEO Pay Median Employee Pay CEO Pay Ratio
Linda Rendle CEO Pay $13,333,032 Median Employee Pay $79,721 CEO Pay Ratio 167:1
For its 2025 fiscal year, CLOROX CO/DE, listed the following board members on its annual proxy statement to the SEC.
Name Total COMPENSATION
A. D. David Mackay Total Cash $270,000
Amy L. Banse Total Cash $81,766
Christopher J. Williams Total Cash $292,184
Esther Lee Total Cash $285,000
Gina Boswell Total Cash $12,404
Julia Denman Total Cash $270,000
Kathryn Tesija Total Cash $81,766
Matthew J. Shattock Total Cash $370,000
Paul Parker Total Cash $81,766
Pierre R. Breber Total Cash $149,800
Russell J. Weiner Total Cash $272,253
Spencer C. Fleischer Total Cash $287,747
Stephanie Plaines Total Cash $270,000
Stephen B. Bratspies Total Cash $146,984
Browse Board of Directors By First Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Browse Executives by First Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Browse Companies by Company Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

This report is not for commercial use. Thorough reviews have been conducted to assure this data accurately reflects disclosures. However for a complete and definitive understanding of the pay practices of any company, users should refer directly to the actual, complete proxy statement.

Use of Data / Disclaimer

The information shown here is a reporting of information included in the company's proxy statement. The proxy statement includes footnotes and explanations of this information plus other information that is pertinent in assessing the overall value and appropriateness of the compensation information. For those interested in conducting a detailed compensation analysis, we recommend that you review the entire proxy statement. You may retrieve the full proxy statement by going to the Securities and Exchange Commission (SEC) website at www.sec.gov and entering the company's name and then looking in the first column for an entry of "Form DEF 14A" (or any similar code). You may also find the annual proxy statement by going directly to the company's website.

What is a proxy statement?

A proxy statement (or "proxy") is a form that every publicly traded U.S. company is required to file with the U.S. Securities & Exchange Commission (SEC) within 120 days after the end of its fiscal year. The proxy must be sent to every shareholder in advance of the company's annual shareholders meeting. All proxy statements are public filings made available to the general public by the SEC.

The proxy statement's main purpose is to alert shareholders to the annual meeting and provide them information about the issues that will be voted on during the annual meeting, including decisions such as electing directors, ratifying the selection of auditors, and other shareholder-related decisions, including shareholder-initiated initiatives. Also, proxies must disclose specific detailed information regarding the pay practices for certain executives.